Status:
UNKNOWN
Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
Lead Sponsor:
Sun Yat-sen University
Conditions:
Hepatocellular Carcinoma
RFA
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The combination of transcatheter arterial chemoembolization (TACE) with RFA has also reported to be an effective treatment for HCC. Studies have shown TACE combined RFA to have better efficacy than RF...
Detailed Description
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy and liver transplantation are considered to be standard curative therapies for HCC. When surgery is not...
Eligibility Criteria
Inclusion
- age 18 - 75 years;
- Distant recurrence of HCC after initial curative treatment (including initial RFA or hepatectomy);
- no other treatment received except for the initial RFA or hepatectomy;
- Single tumor less than 4cm in diameter;
- lesions visible on ultrasound and with an acceptable and safe path between the lesion and the skin as shown on ultrasound;
- no severe coagulation disorders (prothrombin activity \< 40% or a platelet count of \< 40,000 / mm3;
- Eastern Co-operative Oncology Group performance(ECOG) status 0 -
Exclusion
- the presence of vascular invasion or extrahepatic spread on imaging;
- a Child-Pugh class C liver cirrhosis or evidence of hepatic decompensation including ascites, severe coagulation disorders (prothrombin activity \< 40% or a platelet count of \< 40,000 / mm3), esophageal or gastric variceal bleeding or hepatic encephalopathy;
- an American Society of Anesthesiologists (ASA) score ≥ 3
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2014
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01415063
Start Date
February 1 2011
End Date
March 1 2014
Last Update
August 11 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Center, Sun Yat-set University
Guangzhou, Guangdong, China, 510060